# A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).

> **NCT05240131** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Galecto Biotech AB** · enrollment: 88 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** GB1211
- **DRUG:** Placebo
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT05240131
- **Lead sponsor:** Galecto Biotech AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-15
- **Primary completion:** 2024-05-30
- **Final completion:** 2025-11-01
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2024-04-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05240131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05240131, "A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05240131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*